Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.
The US Attorney's Office for the Southern District of New York is examining how Teva has marketed MS drug Copaxone and Parkinson's medication Azilect since 2006.
The company will shell out $2.2 billion over allegations of marketing misconduct for Risperdal, Invega and Natrecor.
The Swiss drug maker is defending itself against two civil fraud lawsuits filed within a week of each other.
Amgen "marketed the spread" between the price practices pay for Aranesp and that patients pay as a means of driving sales—to the point of having speakers tell docs that they could make a million more each year by prescribing the Amgen anemia drug over its competitor, Procrit.
*Group discounts available on request
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.